| Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge (NCT03838731) | Regeneron Pharmaceuticals | 2019-02-12 |
| To Assess the Patients' Ability to Self-Administer Fasinumab (NCT03491904) | Regeneron Pharmaceuticals | 2019-01-23 |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (NCT03761108) | Regeneron Pharmaceuticals | 2019-01-23 |
| Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis (NCT03736967) | Regeneron Pharmaceuticals | 2018-11-12 |
| Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy (NCT04173442) | Regeneron Pharmaceuticals | 2018-10-24 |
| Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee (NCT03691974) | Regeneron Pharmaceuticals | 2018-10-15 |
| Long Term Safety Study of PRALUENT (NCT03694197) | Regeneron Pharmaceuticals | 2018-09-28 |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma (NCT03690869) | Regeneron Pharmaceuticals | 2018-09-24 |
| Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) (NCT03633617) | Regeneron Pharmaceuticals | 2018-09-24 |
| Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers (NCT03645746) | Regeneron Pharmaceuticals | 2018-08-23 |
| REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (NCT03515629) | Regeneron Pharmaceuticals | 2018-07-02 |
| Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis (NCT03452228) | Regeneron Pharmaceuticals | 2018-06-07 |
| A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (NCT03430063) | Regeneron Pharmaceuticals | 2018-05-29 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340) | Regeneron Pharmaceuticals | 2018-05-21 |
| A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers (NCT03530514) | Regeneron Pharmaceuticals | 2018-04-24 |
| Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (NCT03428646) | Regeneron Pharmaceuticals | 2018-04-06 |
| Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer (NCT03438318) | Regeneron Pharmaceuticals | 2018-03-15 |
| Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia (NCT03409744) | Regeneron Pharmaceuticals | 2018-03-13 |
| A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (NCT03188666) | Regeneron Pharmaceuticals | 2018-02-26 |
| Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia (NCT03399786) | Regeneron Pharmaceuticals | 2018-01-18 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) (NCT03346434) | Regeneron Pharmaceuticals | 2017-11-30 |
| Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) (NCT03345914) | Regeneron Pharmaceuticals | 2017-11-17 |
| Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia (NCT03175367) | Regeneron Pharmaceuticals | 2017-11-10 |
| Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (NCT03285646) | Regeneron Pharmaceuticals | 2017-10-30 |
| Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (NCT03304379) | Regeneron Pharmaceuticals | 2017-10-26 |
| Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (NCT03156621) | Regeneron Pharmaceuticals | 2017-10-03 |
| Study of Cemiplimab in Adults With Cervical Cancer (NCT03257267) | Regeneron Pharmaceuticals | 2017-09-05 |